Aoki Diabetes Research Institute

CIIIT Treatment Results

After 6 weeks to 3 months of weekly CIIIT (metabolic activation therapy), patients report improvement in blood glucose control including reduced number of hypoglycemic episodes. Patients also note higher energy levels, and improved wound healing.

After 3 to 12 months of therapy, many patients report stabilization of diabetic complications of the eye, kidney, and heart. These responses are documented by their physician specialists.

List of Published Benefits seen in patients with severe diabetes

  • Improves blood glucose control.
  • Reduces the severity of swings in blood glucose levels in patients with "brittle" diabetes.
  • Restores hypoglycemia awareness.
  • Decreases episodes of severe hypoglycemia by approximately 98 percent.
  • Slows the progression of diabetic kidney.
  • Lowers high blood pressure in diabetic patients.
  • Eliminates dizziness/ blackouts due to orthostatic hypotension.
  • Patients "have more energy"

Additional Benefits seen in patients with severe diabetes but not yet reported in the scientific literature

  • Improves peripheral neuropathy
  • Improves gastroparesis
  • Accelerates wound healing.
  • Improves heart metabolism.
  • Stabilizes diabetic retinopathy.

For further information on treatment results see Patients and Research

Return to top of this page

Copyright 2003-6  Aoki Diabetes Research Institute. ALL RIGHTS RESERVED

 

FAQs

Patients

Physiology

Research

About CIIIT (MAT)

ADRI Home

Metabolic activation therapy (MAT) is another name for chronic intermittent intravenous insulin therapy (CIIIT).